- Language: English
- 369 Pages
- Published: August 2015
- Region: Global
Nanotechnology Drug Delivery Market in the US 2012-2016
- ID: 2510370
- March 2013
- Region: United States
- 30 Pages
TechNavio's analysts forecast the Nanotechnology Drug Delivery market in the US to grow at a CAGR of 84.79 percent over the period 2012-2016. One of the key factors contributing to this market growth is the low R and D cost. The Nanotechnology Drug Delivery market in the US has also been witnessing the trend of emergence of personalized medicines. However, the increasing safety concerns could pose a challenge to the growth of this market.
TechNavio's report, the Nanotechnology Drug Delivery Market in the US 2012-2016, has been prepared based on an in-depth market analysis with inputs from industry experts. It also covers the Nanotechnology Drug Delivery market in the US landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors dominating this space include Alkermes plc.,Celgene Corp., Novartis AG and SkyePharma plc .
Other vendors mentioned in the report are Merck and Co. Inc., Pfizer Inc., AlphaRx Inc., Amgen, Inc., Angiotech Pharmaceuticals, Inc., Biophan
Technologies, Inc., Calando Pharmaceuticals, Inc., Cephalon, Inc., Cerulean Pharma, Inc, Copernicus Therapeutics, Inc., CritiTech, Inc., CytImmune Sciences, Inc., Elan Corporation, plc, Debiotech SA, F. Hoffmann-La Roche Ltd, Nano Interface Technology, Inc, Spherics, Inc., Spectrum Pharmaceuticals, Inc., SoluBest Ltd., Sigma-Tau Pharmaceuticals, Inc., PharmaNova Inc. Particle Sciences, Inc., Novavax, Inc., Nanotherapeutics, Inc., NanoSight Ltd., NanoCarrier Co. Ltd., NanoBioMagnetics, Inc., Nano Interface Technology, Inc, Merck Sharp and Dohme Corp., Kuecept Ltd., Izon Science Ltd.
Key questions answered in this report:
- What will the market size be in 2016 and at what will be the growth rate?
- What are key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by key vendors?
- What are the strengths and weaknesses of each of these key vendors?
The report is also available as part of our annual subscription offer. Please get in touch with our customer service team in order to find out more. SHOW LESS READ MORE >
01. Executive Summary
02. List of Abbreviations
04. Scope of the Report
05. Market Landscape
05.1 Nanotechnology Drug Delivery Market in the US
Market Size and Forecast
05.2 Global Nanotechnology Drug Delivery Market Segmentation
05.3 Five Force Analysis
06. Vendor Landscape
07. Buying Criteria
08. Market Growth Drivers
09. Drivers and their Impact
10. Market Challenges
11. Impact of Drivers and Challenges
12. Market Trends
13. Key Vendor Analysis
13.1 Alkermes plc
13.2 Celgene Corp.
13.3 SkyePharma plc
13.4 Novartis AG
14. Other Reports in this Series
List of Exhibits:
Exhibit 1: Nanotechnology Drug Delivery Market in the US 2012-2016(US$ million)
Exhibit 2: Global Nanotechnology Drug Delivery Market Segmentation by Technology
Exhibit 3: Global Nanotechnology Drug Delivery Market Segmentation 2012(percent)
TechNavio Announces the Publication of its Research Report - Nanotechnology Drug Delivery Market in the US 2012-2016
TechNavio today launched its report Nanotechnology Drug Delivery Market in the US 2012-2016 based on an in-depth analysis covering the US region. The report aims to aid decision makers' understanding of the present and future landscape of the market.
Commenting on the report, an analyst from TechNavio's Healthcare team said: 'Over the years, the research activities in healthcare have changed significantly. There has been a paradigm shift away from blockbusters drugs to a more personalized medicine approach. The focus is being placed increasingly on formulating drugs based on the individual's unique genome and immune response. Personalized medicines have gained significant popularity because they enable the medical profession to provide customized treatment to patients. A customized treatment is based on the genetic as well as medical profile of a patient. Increasing knowledge about the molecular causes of diseases is increasing the demand for more targeted and effective nanotechnology-enabled drug delivery therapies.'
According to the report, one of the most important applications of nanotechnology in medicine currently being developed involves employing nanoparticles to deliver drugs to specific types of cells (such as cancer cells). Nanotechnology drug delivery helps in delivering drugs directly to diseased cells, which allows direct treatment of those cells. This technique helps to avoid damage to healthy cells within the human body. Hence, drug delivery technology helps to increase the overall market success of a particular drug.
Further, the report states that one of the main challenges is the increasing safety concerns. Studies have revealed that the use of various nanomaterials may cause a variety of toxic effects. Lack of FDA directives is another major factor hampering the growth of the Nanotechnology Drug Delivery market in the US.
The report also includes a discussion of the key vendors operating in this market. The key vendors dominating this market space are Alkermes plc, Celgene Corp., Novartis AG, and SkyePharma plc.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
- Alkermes plc
- AlphaRx Inc.
- Amgen Inc.
- Angiotech Pharmaceuticals Inc.
- Biophan Technologies Inc.
- Calando Pharmaceuticals Inc.
- Celgene Corp.
- Cephalon Inc.
- Cerulean Pharma Inc
- Copernicus Therapeutics Inc.
- CritiTech Inc.
- CytImmune Sciences Inc.
- Debiotech SA
- Elan Corp. plc
- F. Hoffmann-La Roche Ltd.
- GlaxoSmithKline plc
- IOTA NanoSolutions Ltd.
- Izon Science Ltd.
- Kuecept Ltd.
- Lena Nanoceutics Ltd.
- Merck & Co. Inc.
- Merck Sharp & Dohme Corp.
- Nano Interface Technology Inc
- Nano Interface Technology Inc.
- NanoBioMagnetics Inc.
- NanoCarrier Co. Ltd.
- NanoSight Ltd.
- Nanotherapeutics Inc.
- Novartis AG
- Novavax Inc.
- Particle Sciences Inc.
- Pfizer Inc.
- PharmaNova Inc.
- Sigma-Tau Pharmaceuticals Inc.
- SkyePharma plc.
- SoluBest Ltd.
- Spectrum Pharmaceuticals Inc.
- Spherics Inc.